{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:29:32Z","timestamp":1788121772575,"version":"build-2803163510"},"reference-count":156,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jfma.2022.10.010","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T08:59:51Z","timestamp":1667638791000},"page":"442-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascular comorbidities"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-0283","authenticated-orcid":false,"given":"Ching-Chi","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-1166","authenticated-orcid":false,"given":"Yen-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6354-7714","authenticated-orcid":false,"given":"Ting-Hsing","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Min","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-9707","authenticated-orcid":false,"given":"Hsien-Yi","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Yi","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hsun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Huei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwo-Chang","family":"Ueng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chieh","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1088-2409","authenticated-orcid":false,"given":"Nan-Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-5532","authenticated-orcid":false,"given":"Charles","family":"Jia-Yin Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2022.10.010_bib1","author":"World Health Organization"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jdermsci.2016.08.535","article-title":"Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: a nationwide, population-based observational study in Taiwan","volume":"84","author":"Wang","year":"2016","journal-title":"J Dermatol Sci"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1684\/ejd.2012.1802","article-title":"Prevalence of psoriasis in China: a population-based study in six cities","volume":"22","author":"Ding","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006450","article-title":"Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database","volume":"5","author":"Kubota","year":"2015","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.5021\/ad.2017.29.6.761","article-title":"Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean national health insurance database","volume":"29","author":"Lee","year":"2017","journal-title":"Ann Dermatol"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","article-title":"Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/1346-8138.15803","article-title":"Epidemiological survey of the psoriasis patients in the Japanese Society for psoriasis Research from 2013 to 2018","volume":"48","author":"Kamiya","year":"2021","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3899\/jrheum.170516","article-title":"Epidemiology and medication pattern change of psoriatic diseases in Taiwan from 2000 to 2013: a nationwide, population-based cohort study","volume":"45","author":"Wei","year":"2018","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib11","first-page":"795","article-title":"Clinical characteristics of Thai patients with psoriasis","volume":"95","author":"Jiamton","year":"2012","journal-title":"J Med Assoc Thai"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib12","first-page":"112","article-title":"Epidemiology of psoriasis in Malaysia: a hospital based study","volume":"65","author":"Sinniah","year":"2010","journal-title":"Med J Malaysia"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients","volume":"30","author":"Torre Alonso","year":"1991","journal-title":"Br J Rheumatol"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.dsi.2018.06.001","article-title":"Psoriasis in Taiwan: from epidemiology to new treatments","volume":"36","author":"Chiu","year":"2018","journal-title":"Dermatol Sin"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.dsi.2016.05.004","article-title":"Health-state utility, willingness to pay, and quality of life among Taiwanese patients with psoriasis","volume":"34","author":"Ko","year":"2016","journal-title":"Dermatol Sin"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.dsi.2018.06.006","article-title":"Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan","volume":"36","author":"Tsai","year":"2018","journal-title":"Dermatol Sin"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/ds.ds_33_19","article-title":"Association of psoriasis with asthma: a systematic review and meta-analysis of observational studies","volume":"38","author":"Fang","year":"2020","journal-title":"Dermatol Sin"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/ds.ds_55_20","article-title":"Risk of chronic kidney disease and end-stage renal disease in patients with psoriasis: a systematic review and meta-analysis of cohort studies","volume":"39","author":"Yang","year":"2021","journal-title":"Dermatol Sin"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4103\/ds.ds_27_20","article-title":"Changes in metabolic parameters in psoriasis patients treated with interleukin-12\/23 blockade (ustekinumab)","volume":"38","author":"Ng","year":"2020","journal-title":"Dermatol Sin"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"issue":"9997","key":"10.1016\/j.jfma.2022.10.010_bib22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jaad.2018.02.040","article-title":"Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis","volume":"79","author":"Lockshin","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","article-title":"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same?","volume":"46","author":"Coates","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"10136","key":"10.1016\/j.jfma.2022.10.010_bib26","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/ds.ds_53_20","article-title":"Correlation of clinical diagnosis of dactylitis by the dermatologist and ultrasonographic diagnosis by the rheumatologist in patients with psoriasis arthritis: experience of a single clinic","volume":"39","author":"Lo","year":"2021","journal-title":"Dermatol Sin"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the rule of tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/ds.ds_35_19","article-title":"Association of the attachment styles with depression, anxiety, and quality of life in patients with psoriasis","volume":"38","author":"Demirci","year":"2020","journal-title":"Dermatol Sin"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/TCRM.S2740","article-title":"Moderate and severe plaque psoriasis: cost-of-illness study in Italy","volume":"4","author":"Colombo","year":"2008","journal-title":"Therapeut Clin Risk Manag"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib34","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib35","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib36","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/09546634.2017.1294727","article-title":"Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab","volume":"28","author":"Elewski","year":"2017","journal-title":"J Dermatol Treat"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.dsi.2017.01.002","article-title":"Taiwanese Dermatological Association consensus statement on management of psoriasis","volume":"35","author":"Tsai","year":"2017","journal-title":"Dermatol Sin"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib39","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jfma.2020.08.026","article-title":"Recommendations for psoriatic arthritis management: a joint position paper of the Taiwan rheumatology association and the Taiwanese association for psoriasis and skin Immunology","volume":"120","author":"Tsai","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2022.10.010_bib40","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences","volume":"9","author":"Boehncke","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jfma.2022.10.010_bib41","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2147\/JIR.S282691","article-title":"Effect of biologics on cardiovascular inflammation: mechanistic insights and risk reduction","volume":"14","author":"Fragoulis","year":"2021","journal-title":"J Inflamm Res"},{"issue":"12","key":"10.1016\/j.jfma.2022.10.010_bib42","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jfma.2022.10.010_bib43","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1056\/NEJM197304262881715","article-title":"Occlusive vascular disease in psoriatic patients","volume":"288","author":"McDonald","year":"1973","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jfma.2022.10.010_bib44","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.amjcard.2011.11.025","article-title":"Coronary artery disease in patients with psoriasis referred for coronary angiography","volume":"109","author":"Armstrong","year":"2012","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","article-title":"Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis","volume":"159","author":"Kaye","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00403-013-1437-3","article-title":"High prevalence of cardiovascular risk factors in patients with moderate or severe psoriasis in northern China","volume":"306","author":"Ma","year":"2014","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"10.1016\/j.jfma.2022.10.010_bib47","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaad.2017.03.037","article-title":"Real-world burden of comorbidities in US patients with psoriasis","volume":"77","author":"Shah","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"10.1016\/j.jfma.2022.10.010_bib49","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib50","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2133.2011.10774.x","article-title":"Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study","volume":"166","author":"Li","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1346-8138.2011.01401.x","article-title":"Psoriasis and increased risk of ischemic stroke in Taiwan: a nationwide study","volume":"39","author":"Chiang","year":"2012","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2015.06.023","article-title":"Increased risk of arrhythmia in patients with psoriatic disease: a nationwide population-based matched cohort study","volume":"73","author":"Chiu","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib53","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2016.06.002","article-title":"Increased risk of aortic aneurysm (AA) in relation to the severity of psoriasis: a national population-based matched-cohort study","volume":"75","author":"Chiu","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib54","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jaad.2010.01.050","article-title":"Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan","volume":"64","author":"Lin","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jfma.2022.10.010_bib55","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1468-3083.2012.04599.x","article-title":"Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy","volume":"27","author":"Su","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib56","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1365-2133.2011.10494.x","article-title":"Medical comorbidity associated with psoriasis in adults: a population-based study","volume":"165","author":"Yang","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib58","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1016\/j.ijcard.2013.07.127","article-title":"Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies","volume":"168","author":"Gu","year":"2013","journal-title":"Int J Cardiol"},{"issue":"Suppl 3","key":"10.1016\/j.jfma.2022.10.010_bib59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jdv.12163","article-title":"Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review","volume":"27","author":"Horreau","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jfma.2022.10.010_bib60","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis","volume":"133","author":"Samarasekera","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib61","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/bjd.12002","article-title":"Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies","volume":"167","author":"Xu","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib62","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ijcard.2013.01.197","article-title":"Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis","volume":"168","author":"Gaeta","year":"2013","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib63","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2796.2011.02368.x","article-title":"Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J Intern Med"},{"issue":"7","key":"10.1016\/j.jfma.2022.10.010_bib64","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jid.2017.01.036","article-title":"All-cause and cause-specific mortality in patients with psoriasis in Taiwan: a nationwide population-based study","volume":"137","author":"Lee","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.jfma.2022.10.010_bib65","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1346-8138.15052","article-title":"Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: a 15-year nationwide population-based cohort study","volume":"46","author":"Jung","year":"2019","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib66","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/joim.13311","article-title":"Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multi-centre cohort study","volume":"290","author":"Tinggaard","year":"2021","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib67","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","article-title":"Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality","volume":"145","author":"Prodanovich","year":"2009","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.jfma.2022.10.010_bib68","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/jid.2015.87","article-title":"Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice Research datalink","volume":"135","author":"Parisi","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jfma.2022.10.010_bib69","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archinte.161.7.996","article-title":"Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study","volume":"161","author":"He","year":"2001","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.jfma.2022.10.010_bib70","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ejhf.113","article-title":"Psoriasis and risk of heart failure: a nationwide cohort study","volume":"16","author":"Khalid","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib71","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12872-021-01972-0","article-title":"Psoriasis as risk factor for non-ischemic dilated cardiomyopathy: a population-based cross-sectional study","volume":"21","author":"Alshami","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib72","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000121605","article-title":"Psoriasis and dilated cardiomyopathy: coincidence or associated diseases?","volume":"111","author":"Eliakim-Raz","year":"2008","journal-title":"Cardiology"},{"key":"10.1016\/j.jfma.2022.10.010_bib73","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.930041","article-title":"Nonischemic dilated cardiomyopathy in untreated long-term psoriatic arthritis: a newly recognized association: a case report with mini review","volume":"22","author":"Alfraji","year":"2021","journal-title":"Am J Case Rep"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib74","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2133.1998.02085.x","article-title":"Psoriatic arthritis associated with dilated cardiomyopathy and Takayasu's arteritis","volume":"138","author":"Fukuhara","year":"1998","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib75","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/0019-5154.70689","article-title":"Deepshikha. Psoriasis and cardiomyopathy: an intriguing association","volume":"55","author":"Prakash","year":"2010","journal-title":"Indian J Dermatol"},{"issue":"9","key":"10.1016\/j.jfma.2022.10.010_bib76","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.autrev.2014.05.007","article-title":"Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation","volume":"13","author":"Lazzerini","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/oxfordjournals.eurheartj.a062058","article-title":"Ambulatory 24-hour continuous electrocardiographic monitoring in 54 patients with ankylosing spondylitis","volume":"7","author":"Thomsen","year":"1986","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib78","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1253\/circj.CJ-19-0705","article-title":"Cardiac arrhythmias in autoimmune diseases","volume":"84","author":"Gawa\u0142ko","year":"2020","journal-title":"Circ J"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib79","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4103\/0378-6323.186480","article-title":"Psoriasis and risk of incident atrial fibrillation: a systematic review and meta-analysis","volume":"82","author":"Ungprasert","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib80","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjd.13778","article-title":"Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study","volume":"173","author":"Egeberg","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jfma.2022.10.010_bib81","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/901215","article-title":"Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients","volume":"2013","author":"Simsek","year":"2013","journal-title":"Sci World J"},{"issue":"12","key":"10.1016\/j.jfma.2022.10.010_bib82","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1161\/ATVBAHA.115.306460","article-title":"Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET\/CT and neutrophil activation in a prospective observational study","volume":"35","author":"Naik","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.jfma.2022.10.010_bib83","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/clc.23438","article-title":"Risk of aortic aneurysm in patients with psoriasis: a systematic review and meta-analysis of cohort studies","volume":"43","author":"Yu","year":"2020","journal-title":"Clin Cardiol"},{"issue":"9468","key":"10.1016\/j.jfma.2022.10.010_bib84","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jfma.2022.10.010_bib85","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1161\/CIRCULATIONAHA.105.539528","article-title":"Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus","volume":"112","author":"Wilson","year":"2005","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1016\/j.jfma.2022.10.010_bib86","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1038\/ijo.2008.30","article-title":"Cardiometabolic risk: a Framingham perspective","volume":"32","author":"Wilson","year":"2008","journal-title":"Int J Obes"},{"issue":"17","key":"10.1016\/j.jfma.2022.10.010_bib87","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, Lung, and blood institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jfma.2022.10.010_bib88","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2337\/diacare.28.9.2289","article-title":"The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"28","author":"Kahn","year":"2005","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.jfma.2022.10.010_bib89","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","article-title":"Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib90","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jid.2018.09.021","article-title":"Antagonization of IL-17a attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis","volume":"139","author":"Sch\u00fcler","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib91","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/CIRCRESAHA.116.304794","article-title":"Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling","volume":"116","author":"Subramanian","year":"2015","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.jfma.2022.10.010_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161548","article-title":"Role of pro-inflammatory cytokines and biochemical markers in the pathogenesis of type 1 diabetes: correlation with age and glycemic condition in diabetic human subjects","volume":"11","author":"Fatima","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib93","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cmet.2015.05.020","article-title":"Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling","volume":"22","author":"Monteiro-Sepulveda","year":"2015","journal-title":"Cell Metabol"},{"issue":"8","key":"10.1016\/j.jfma.2022.10.010_bib94","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3 Pt 1","key":"10.1016\/j.jfma.2022.10.010_bib95","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib96","first-page":"537","article-title":"Consensus statement of the Taiwan hypertension Society and the Taiwan Society of cardiology on home blood pressure monitoring for the management of arterial hypertension","volume":"36","author":"Lin","year":"2020","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.jfma.2022.10.010_bib97","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1084\/jem.20090545","article-title":"Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis","volume":"206","author":"Taleb","year":"2009","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.jfma.2022.10.010_bib98","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.4049\/jimmunol.0901126","article-title":"Inhibition of IL-17A attenuates atherosclerotic lesion development in ApoE-deficient mice","volume":"183","author":"Erbel","year":"2009","journal-title":"J Immunol"},{"issue":"196","key":"10.1016\/j.jfma.2022.10.010_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006133","article-title":"Transforming growth factor-\u03b2 signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway","volume":"5","author":"Gister\u00e5","year":"2013","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.jfma.2022.10.010_bib100","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.ATV.0000143933.20616.1b","article-title":"Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice","volume":"24","author":"Br\u00e5n\u00e9n","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2004.11.016","article-title":"Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice","volume":"180","author":"Ohta","year":"2005","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cardiores.2005.01.001","article-title":"Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE\u22173-Leiden transgenic mice","volume":"66","author":"Boesten","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jfma.2022.10.010_bib103","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.atherosclerosis.2018.08.030","article-title":"Anti-tumor necrosis factor-\u03b1 therapy increases plaque burden in a mouse model of experimental atherosclerosis","volume":"277","author":"Oberai","year":"2018","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib104","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib106","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib107","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib108","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1540-9740.2005.04502.x","article-title":"TNF-alpha inhibitors and congestive heart failure","volume":"4","author":"Behnam","year":"2005","journal-title":"Skinmed"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib109","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2011.07.040","article-title":"Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis","volume":"67","author":"Pariser","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jfma.2022.10.010_bib110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11886-018-1067-7","article-title":"Tumor necrosis factor-alpha in heart failure: an updated review","volume":"20","author":"Schumacher","year":"2018","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib111","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejim.2012.12.015","article-title":"Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases","volume":"24","author":"Sinagra","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"25","key":"10.1016\/j.jfma.2022.10.010_bib112","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib113","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib114","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2018.02.074","article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3","volume":"79","author":"Egeberg","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jfma.2022.10.010_bib115","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatology"},{"issue":"10148","key":"10.1016\/j.jfma.2022.10.010_bib116","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jfma.2022.10.010_bib117","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib118","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib119","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/bjd.17454","article-title":"Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies","volume":"180","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib120","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.jfma.2022.10.010_bib121","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","article-title":"The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids","volume":"60","author":"Persson","year":"2021","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.jfma.2022.10.010_bib122","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.jfma.2022.10.010_bib124","first-page":"772","article-title":"Acitretin in dermatology: a review","volume":"10","author":"Dunn","year":"2011","journal-title":"J Drugs Dermatol JDD"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib125","first-page":"301","article-title":"Exploring cyclosporine A-side effects and the protective role-played by antioxidants: the morphological and immunohistochemical studies","volume":"21","author":"Rezzani","year":"2006","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.jfma.2022.10.010_bib126","first-page":"CD007893","article-title":"Effect of cyclosporine on blood pressure","volume":"1","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib127","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1038\/s41598-021-87766-y","article-title":"The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study","volume":"11","author":"Hong","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib128","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib129","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/ijd.14246","article-title":"Review of safety and efficacy of approved systemic psoriasis therapies","volume":"58","author":"Kaushik","year":"2019","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.jfma.2022.10.010_bib131","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1468-3083.2012.04706.x","article-title":"Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study","volume":"27","author":"Chin","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfma.2022.10.010_bib132","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2340\/00015555-1283","article-title":"Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study","volume":"92","author":"Lan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jfma.2022.10.010_bib133","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CLEP.S305126","article-title":"Cardiovascular risk associated with methotrexate versus retinoids in patients with psoriasis: a nationwide Taiwanese cohort study","volume":"13","author":"Tsai","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib134","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2340\/0001555575391392","article-title":"Methotrexate-linked ventricular arrhythmias","volume":"75","author":"Kettunen","year":"1995","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.jfma.2022.10.010_bib135","first-page":"517","article-title":"Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis","volume":"72","author":"Wooten","year":"2000","journal-title":"Del Med J"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib136","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/03009740600991869","article-title":"Right bundle branch block induced by low-dose methotrexate in a patient with rheumatoid arthritis","volume":"36","author":"Thonhofer","year":"2007","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib137","first-page":"1004","article-title":"Repetitive exercise induced ventricular tachycardia in a patient with rheumatoid arthritis taking low dose methotrexate","volume":"19","author":"Borek","year":"1992","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib138","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4081\/reumatismo.2016.869","article-title":"Possible relationship between certolizumab pegol and arrhythmias: report of two cases","volume":"68","author":"Talotta","year":"2016","journal-title":"Reumatismo"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib139","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/1756-185X.12986","article-title":"Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: a nationwide population-based retrospective cohort study","volume":"20","author":"Tam","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib140","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/1570161117666190930113837","article-title":"Cardiovascular risk of synthetic, non-biologic disease-modifying anti- rheumatic drugs (DMARDs)","volume":"18","author":"Mourouzis","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib141","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/ard.61.6.567","article-title":"Leflunomide and hypertension","volume":"61","author":"Rozman","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib142","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/000331970205300617","article-title":"Beta-blocker-induced psoriasis: a rare side effect-a case report","volume":"53","author":"Yilmaz","year":"2002","journal-title":"Angiology"},{"issue":"12","key":"10.1016\/j.jfma.2022.10.010_bib143","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1365-4632.2010.04570.x","article-title":"The role of drugs in the induction and\/or exacerbation of psoriasis","volume":"49","author":"Basavaraj","year":"2010","journal-title":"Int J Dermatol"},{"issue":"9","key":"10.1016\/j.jfma.2022.10.010_bib144","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamadermatol.2013.9957","article-title":"Hypertension, antihypertensive medication use, and risk of psoriasis","volume":"150","author":"Wu","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib145","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2008.08563.x","article-title":"Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study","volume":"158","author":"Brauchli","year":"2008","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jfma.2022.10.010_bib146","article-title":"Mechanisms of beta-blocker induced psoriasis, and psoriasis de novo at the cellular level","volume":"12","author":"Awad","year":"2020","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.jfma.2022.10.010_bib147","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1080\/15548627.2019.1686728","article-title":"Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells","volume":"16","author":"Muller","year":"2020","journal-title":"Autophagy"},{"issue":"6","key":"10.1016\/j.jfma.2022.10.010_bib148","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clindermatol.2007.08.015","article-title":"Triggering psoriasis: the role of infections and medications","volume":"25","author":"Fry","year":"2007","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib149","article-title":"A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence","volume":"11","author":"Song","year":"2021","journal-title":"Sci Rep"},{"issue":"6609","key":"10.1016\/j.jfma.2022.10.010_bib150","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/bmj.295.6609.1352","article-title":"Does captopril exacerbate psoriasis?","volume":"295","author":"Hamlet","year":"1987","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.jfma.2022.10.010_bib151","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1540-9740.2006.04515.x","article-title":"Psoriatic erythroderma associated with enalapril","volume":"5","author":"Antonov","year":"2006","journal-title":"Skinmed"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib152","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MJT.0b013e31818f9e99","article-title":"Ramipril-induced generalized pustular psoriasis: case report and literature review","volume":"17","author":"Thakor","year":"2010","journal-title":"Am J Therapeut"},{"issue":"9","key":"10.1016\/j.jfma.2022.10.010_bib153","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14740338.2018.1508446","article-title":"Psoriasis during angiotensin receptor blocker exposure: an underestimated adverse drug reaction","volume":"17","author":"Azzouz","year":"2018","journal-title":"Expet Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib154","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.therap.2020.05.013","article-title":"Calcium channel blocker exposure and psoriasis risk: pharmacovigilance investigation and literature data","volume":"76","author":"Azzouz","year":"2021","journal-title":"Therapie"},{"issue":"5","key":"10.1016\/j.jfma.2022.10.010_bib155","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/1346-8138.15281","article-title":"Digoxin use and following risk of psoriasis: a population-based cohort study in Taiwan","volume":"47","author":"Li","year":"2020","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2022.10.010_bib156","first-page":"213","article-title":"The 2017 focused update of the guidelines of the Taiwan Society of cardiology (TSOC) and the Taiwan hypertension Society (THS) for the management of hypertension","volume":"33","author":"Chiang","year":"2017","journal-title":"Acta Cardiol Sin"},{"issue":"1","key":"10.1016\/j.jfma.2022.10.010_bib157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcma.2014.11.005","article-title":"Guidelines of the Taiwan Society of cardiology and the Taiwan hypertension Society for the management of hypertension","volume":"78","author":"Chiang","year":"2015","journal-title":"J Chin Med Assoc"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622003941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622003941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:49:44Z","timestamp":1760539784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664622003941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":156,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0929664622003941"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.10.010","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascular comorbidities","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}